Loading the records…
Loading the records…
The PBM FAIR Act (S3549) imposes ERISA fiduciary duty on UNH's Optum Rx, CVS's Caremark, and CI's Express Scripts, eliminating undisclosed rebates and spread pricing. Despite a 30-day rally of +36.2% in UNH, +16.35% in CVS, and +9.1% in CI, this early-stage bill creates a multi-year overhang that would reverse those gains upon legislative progress. Current pricing embeds zero probability of passage — real data shows UNH at $368.56, CVS at $83.56, CI at $291.02.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The PBM FAIR Act creates a multi-year regulatory overhang on the Big 3 PBM stocks. Current market pricing — UNH at $368.56 (up 36.2% in 30 days), CVS at $83.56 (up 16.35%), CI at $291.02 (up 9.1%) — has entirely ignored this risk. A conservative estimate suggests 15-25% downside for these three stocks upon any credible legislative movement (committee markup or CBO score). The asymmetry favors shorts or puts: the bill progressing is not priced in, while the bill dying is already the base case. Investors should monitor Schedule C of the Senate HELP Committee and any CRS reports for early signals of movement.
What happened: Senator Marshall (R-KS) introduced S3549 on December 17, 2025, along with cosponsors Kaine (D-VA), Grassley (R-IA), and Hassan (D-NH). The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. Companion bill HR6837 was introduced in the House. The bill is early-stage — no hearings, no markup, no CBO score. The 119th Congress session runs through January 2027, giving this bill a full calendar year to advance.
Money trail: This bill authorizes $0 in new spending. Its mechanism is regulatory — it redesignates PBMs as ERISA fiduciaries, creating legal obligations and liability. The financial impact is on PBM profit margins, not government appropriations. The bill forces PBMs to disclose and pass through all manufacturer rebates, fees, and price concessions to plan sponsors (employers, unions, insurers). Spread pricing — where PBMs charge plans more than they reimburse pharmacies — is effectively banned because the PBM must report all compensation earned.
Structural winners and losers: The Big 3 PBMs — Optum Rx (UNH), Caremark (CVS), and Express Scripts (CI) — are the direct losers. They would lose an estimated $7-11B in combined annual profit from rebate retention and spread pricing. Smaller, transparent PBMs like Evernorth's competition (e.g., Navitus, SmithRx, Capital Rx — all private) would benefit as plan sponsors shift to fiduciaries. Health insurers with in-house PBMs (UNH, CI) face double impact: reduced PBM profit and potential insurance premium adjustments as rebate pass-throughs lower drug costs for plans. Pharmacy chains (Walgreens/WBA, Rite Aid/RADCQ) may benefit marginally as spread elimination increases pharmacy reimbursement rates.
Real market data analysis: UNH has rallied 36.2% in 30 days to $368.56, but remains below its 52-week high of $411.99. CVS is up 16.35% in 30 days to $83.56, approaching its 52-week high of $85.15. CI is up 9.1% in 30 days to $291.02, well below its 52-week high of $350. The rally appears driven by Q1 2026 earnings beats and broader market rotation into value/healthcare, not by legislative risk reassessment. The 7-day changes (UNH +3.84%, CVS +7.21%, CI +5.58%) show accelerating momentum, suggesting the market is pricing in continued operational strength, not the PBM FAIR Act Overhang. This creates downside risk: any meaningful legislative progress (committee markup, CBO score, floor vote) would trigger a repricing.
Timeline: Early-stage bill with 4 sponsors (2 Republicans, 2 Democrats) — bipartisan but not committee leadership. Grassley (ranking member of Senate Finance) adds weight. A companion bill in the House (HR6837) increases passage probability long-term. Next milestones: committee hearings (6-12 months for a non-priority bill), markup, potential floor vote. Realistically, this bill has a 20-30% chance of passage this Congress, but even hearings would create headline risk for PBM stocks.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
Pharmacists Fight Back in Medicare and Medicaid Act
Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
PBM Act
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →